Hologic (HOLX) Advances While Market Declines: Some Information for Investors

In the latest trading session, Hologic (HOLX) closed at $61.27, marking a +0.67% move from the previous day. The stock's change was more than the S&P 500's daily loss of 0.23%. On the other hand, the Dow registered a loss of 0.91%, and the technology-centric Nasdaq increased by 0.1%.The the stock of medical device maker has fallen by 5.7% in the past month, leading the Medical sector's loss of 10.2% and the S&P 500's loss of 12.13%.Analysts and investors alike will be keeping a close eye on the performance of Hologic in its upcoming earnings disclosure. The company's earnings report is set to go public on May 1, 2025. It is anticipated that the company will report an EPS of $1.02, marking a 0.97% fall compared to the same quarter of the previous year. Meanwhile, the latest consensus estimate predicts the revenue to be $1 billion, indicating a 1.56% decrease compared to the same quarter of the previous year.In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $4.28 per share and a revenue of $4.08 billion, indicating changes of +4.9% and +1.29%, respectively, from the former year.Investors might also notice recent changes to analyst estimates for Hologic. These revisions typically reflect the latest short-term business trends, which can change frequently. Therefore, positive revisions in estimates convey analysts' confidence in the company's business performance and profit potential.Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.03% lower. At present, Hologic boasts a Zacks Rank of #3 (Hold).Digging into valuation, Hologic currently has a Forward P/E ratio of 14.23. This represents a discount compared to its industry's average Forward P/E of 23.48.Meanwhile, HOLX's PEG ratio is currently 2.02. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. HOLX's industry had an average PEG ratio of 2.14 as of yesterday's close.The Medical - Instruments industry is part of the Medical sector. With its current Zacks Industry Rank of 80, this industry ranks in the top 33% of all industries, numbering over 250.The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.You can find more information on all of these metrics, and much more, on Zacks.com.Zacks' Research Chief Names "Stock Most Likely to Double"Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.This top pick is among the most innovative financial firms. With a fast-growing customer base (already 50+ million) and a diverse set of cutting edge solutions, this stock is poised for big gains. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Hologic, Inc. (HOLX): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks